Drug Profile
Pirarubicin
Alternative Names: 1609RB; Pinorubin; Tetrahydropyranyl doxorubicin; Theprubicina; Theprubicine; Therarubicin; THPLatest Information Update: 18 Dec 2021
Price :
$50
*
At a glance
- Originator Institute of Microbial Chemistry
- Developer Almirall S.A.; CSL Behring; Meiji Seika Pharma; Mercian; Nippon Kayaku; Sanofi; sanofi-aventis
- Class Anthracyclines; Cytostatic antibiotics
- Mechanism of Action DNA topoisomerase inhibitors; RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Breast cancer; Cancer
Most Recent Events
- 08 Jan 2007 ZLB Behring is now called CSL Behring
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 01 Apr 2004 Aventis Behring LLC has merged with ZLB Bioplasma to form ZLB Behring